The role of bendamustine in the treatment of mantle cell lymphomas

Bookmark and Share
Published: 28 Feb 2011
Views: 9450
Rating:
Save
Prof Mathias Rummel - Klinikum der Justus-Liebig-Universität, Giessen, Germany
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line treatment for MCL, Prof Rummel outlines his latest results presented at ASH 2010. These results establish the superiority of bendamustine plus rituximab over fludarabine plus rituximab in patients with relapsed MCL in terms of both efficacy and toxicity profile.